eXoZymes Return on Equity

eXoZymes (EXOZ) currently reports a ROE of -278.89%. That is below the Healthcare sector average of -75.59%. Use the charts on this page to explore eXoZymes's ROE history and peer comparisons.

eXoZymes's ROE of -278.89% is lower than the Healthcare sector average of -75.59%. That is roughly 268.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but eXoZymes's current -278.89% should be judged against Healthcare norms (sector average: -75.59%) and against EXOZ's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -278.89%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.59%. From there, open related valuation or income-statement pages for eXoZymes, and consider following EXOZ for alerts when major investors trade the stock.

eXoZymes is classified in the Healthcare sector. On ROE, it currently shows -278.89% versus a sector average near -75.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EXOZ with unrelated industries.